spacer
home > epc
PUBLICATIONS

European Pharmaceutical Contractor

 

European Pharmaceutical Contractor (EPC) is designed to fill a unique position in pharmaceutical publishing. Providing a dedicated platform of communication and information for the international pharmaceutical contract market, it consists of a series of articles and case studies written by eminent figures in contractor groups and traditional multinational pharmaceutical companies.

Each quarterly edition examines areas of importance – both economic and technical – to contract research organisations, contract manufacturers, regulatory controllers, consultants and analysts. This enables regulatory bodies to link directly with policy-makers both in major contractor groups and pharmaceutical companies, and thereby convey regulatory information directly from the governing bodies, but also ensure debate between the policy-makers and consultancy groups.

 

For further information please contact:

Advertising
Jonathan Smith

Editorial
Aimee-Rose O'Driscoll

We're also on Twitter! Follow us @EPCmagazine

View the digital version of EPC




 

epc
 
 
Featured in this issue
Science & Innovation: Cancer Focus
Lung Cancer Treatment

Nano Debate: Part 1

Shelley Bowers from Asons Solicitors debates the pros and cons of using nanotechnology in the treatment of non-small cell lung cancer. Although the tool holds much hope for the future, it should be approached with caution as it lacks thorough research.
Marketplace & Business
Intellectual Property

Enhancing Assets


Jackie Maguire of Coller IP contends that businesses could be doing more to fully utilise their intellectual property portfolios. To accommodate the pressures of change and get the most out of assets, companies should plan ahead and engage outside help.
  Labs & Logistics
Laboratory Relocation

The Right Move


Potential research disruption, damage to samples and heavy costs can strike fear into any company considering a laboratory move. John Best at Andrew Porter Ltd tells us how to make a success of any relocation.

spacer
Edited by
Dr Graham Hughes,
Consultant in
Pharmaceutical
Development
Published quarterly in
March, June,
September and December
Banner of PCI.EPC on Samedan
Banner of Samedan app.EPC on Samedan
Banner of TBM.EPC on Samedan
 
Industry Events

4th Annual Drug Delivery and Formulation Asia Summit

12-14 November 2014, Wyndham Bund East Shanghai Hotel, Shanghai, China

Since 2011 when DDF Asia Summit was launched, with you kindly supports we have went through 3 years. We bring it up as a child with the expectation that more and more people will like it. DDF Asia summit is devoted to adding value to our clients and promoting industry progress.
More info >>

 
News and Press Releases

Comprehend Raises $21 Million in Series B Funding

REDWOOD CITY, CALIF. – August 18, 2014 – Comprehend today announced it has secured $21 million in Series B financing to accelerate clinical development through its cloud-based business intelligence solutions, enabling life science companies to bring new treatments and devices to market faster and more affordably. The round was led by Lightspeed Venture Partners with support from existing investor Sequoia Capital. Lightspeed partner Peter Nieh joined the company’s board of directors.
More info >>

air transport logo

 

White Papers

Mouse Models for Evaluation of Vaccines and Therapeutics Against Staphylococcal Infections

IBT Bioservices

Introduction Staphylococcus aureus (SA) is a ubiquitous, formidable Gram-positive pathogen associated with skin and soft tissue, as well as lifethreatening systemic infections. SA is a leading cause of hospital- and community-associated infections worldwide, affecting humans and animals. The wide range of pathologies reflects the diverse abilities of this microbe to escape the innate and adaptive immune response using virulence factors. Since its first emergence in the 1960s methicillin-resistant SA (MRSA) has become endemic in hospitals and healthcare settings worldwide. In the 1990s, community associated MRSA strains (CA-MRSA) emerged, and are spreading worldwide posing a major global challenge.
More info >>

©2000-2011 Samedan Ltd.
Add to favourites

Print this page

Send to a friend
Privacy statement